Literature DB >> 12715876

N(2)-substituted D,L-cycloserine derivatives: synthesis and evaluation as alanine racemase inhibitors.

Myoung Goo Kim1, Ulrich Strych, Kurt Krause, Michael Benedik, Harold Kohn.   

Abstract

A select series of N(2)-substituted D,L-cycloserine derivatives were prepared a ndevaluated for inhibitory activity against purified alanine racemases (alr gene product) from Escherichia coli, Staphylococcus aureus, and Mycobacterium tuberculosis, as well as in a growth inhibition assay. N(2)-Modification led to loss of enzymatic inhibitory activity in most cases consistent with a recent proposal for cycloserine function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715876     DOI: 10.7164/antibiotics.56.160

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus.

Authors:  Mihai Ciustea; Sara Mootien; Adriana E Rosato; Oriana Perez; Pier Cirillo; Kacheong R Yeung; Michel Ledizet; Michael H Cynamon; Paul A Aristoff; Raymond A Koski; Paul A Kaplan; Karen G Anthony
Journal:  Biochem Pharmacol       Date:  2011-11-29       Impact factor: 5.858

2.  New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis.

Authors:  Karen G Anthony; Ulrich Strych; Kacheong R Yeung; Carolyn S Shoen; Oriana Perez; Kurt L Krause; Michael H Cynamon; Paul A Aristoff; Raymond A Koski
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

3.  Selection and characterization of alanine racemase inhibitors against Aeromonas hydrophila.

Authors:  Yaping Wang; Chao Yang; Wen Xue; Ting Zhang; Xipei Liu; Jiansong Ju; Baohua Zhao; Dong Liu
Journal:  BMC Microbiol       Date:  2017-05-25       Impact factor: 3.605

Review 4.  Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.

Authors:  Moagi Shaku; Christopher Ealand; Bavesh D Kana
Journal:  Front Cell Infect Microbiol       Date:  2020-11-12       Impact factor: 5.293

5.  Purification and preliminary crystallization of alanine racemase from Streptococcus pneumoniae.

Authors:  Ulrich Strych; Milya Davlieva; Joseph P Longtin; Eileen L Murphy; Hookang Im; Michael J Benedik; Kurt L Krause
Journal:  BMC Microbiol       Date:  2007-05-17       Impact factor: 3.605

6.  Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance.

Authors:  Yoshio Nakatani; Helen K Opel-Reading; Matthias Merker; Diana Machado; Sönke Andres; S Siva Kumar; Danesh Moradigaravand; Francesc Coll; João Perdigão; Isabel Portugal; Thomas Schön; Dina Nair; K R Uma Devi; Thomas A Kohl; Patrick Beckert; Taane G Clark; Gugu Maphalala; Derrick Khumalo; Roland Diel; Kadri Klaos; Htin Lin Aung; Gregory M Cook; Julian Parkhill; Sharon J Peacock; Soumya Swaminathan; Miguel Viveiros; Stefan Niemann; Kurt L Krause; Claudio U Köser
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

7.  Purification, Characterization and Inhibition of Alanine Racemase from a Pathogenic Strain of Streptococcus iniae.

Authors:  Murtala Muhammad; Yangyang Li; Siyu Gong; Yanmin Shi; Jiansong Ju; Baohua Zhao; Dong Liu
Journal:  Pol J Microbiol       Date:  2019-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.